The US Food and Drug Administration reprimanded Sprout Pharmaceuticals, Inc. for a radio advertisement for Addyi (flibanserin) that fails to disclose the risk of taking the hypoactive sexual desire disorder drug with alcohol and requested that it issue a corrective piece.
The agency’s Office of Prescription Drug Promotion sent a warning letter to Sprout CEO Cindy Eckert, saying the ad...